Philogen and Sun Pharmaceutical (Sun Pharma) have announced the filing of a marketing authorisation application (MAA) with the European Medicines Agency (EMA) for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.
Interim analysis of the Phase III FIBROSARC trial investigating L19TNF in patients with first-line Soft Tissue Sarcoma
Philogen new production facility in Rosia has received the GMP certificate by Competent Authorities
Philochem (Philogen) and Blue Earth Diagnostic (Bracco) announce the three first patients in the Phase I trial have been imaged with 68Ga-OncoFAP
Nidlegy„¢ Phase III PIVOTAL trial meets the study™s primary objective for patients with locally advanced fully resectable melanoma
Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy, 28th June 2023 “ Philogen S.p.A (BIT: PHIL) today announced that it has...
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy„¢ in combination with MSD anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in stage III and...
Sun Pharmaceutical Industries has reached a licence agreement with Philogen for the commercialisation of Philogen’s Nidlegy (Daromun) in Australia, New Zealand and Europe.
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Z¼rich L19TNF (also known as Fibromun) is an...
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology